Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shen Lu

Showing results (221-230 of 228) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 228 results.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancerRichard R Love, Syed Mozammel Hossain, Md Margub Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Cancer Letters|July 12, 2025
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in TaiwanShao-Chun Wang, Yi-Chun Shen, Mei-Ren Pan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Molecular Cancer|June 4, 2026
Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancerYa-Hsuan Chang, Yi-Ju Chen, Zhi-Jie Hong, et al.
Journal of Breast Cancer|July 6, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer ManagementJiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, et al.
Pageof 23

Showing results (221-230 of 228) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 228 results.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancerRichard R Love, Syed Mozammel Hossain, Md Margub Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.
Cancer Letters|July 12, 2025
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in TaiwanShao-Chun Wang, Yi-Chun Shen, Mei-Ren Pan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Molecular Cancer|June 4, 2026
Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancerYa-Hsuan Chang, Yi-Ju Chen, Zhi-Jie Hong, et al.
Journal of Breast Cancer|July 6, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer ManagementJiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, et al.
Pageof 23